Product Description
an enzyme replacement therapy using plant cell expression technology. aliglucerase alfa is a plant cell-expressed acid beta-glucosidase approved in the United States and other countries for ERT in adults with GD1. (Sourced from: https://pubmed.ncbi.nlm.nih.gov/24630271/)
Mechanisms of Action: Glucocerebroside Hydrolyzer
Novel Mechanism: No
Modality: Peptide/Protein
Route of Administration: Intravenous
FDA Designation: None *
Approval Status: Approved
Approved Countries: Australia | Brazil | Canada | Chile | Dominican Republic | European Medicines Agency | Israel | New Zealand | Peru | Russia | Serbia | South Africa | Taiwan | Turkey | Ukraine | United States | Uruguay
Approved Indications: None
Known Adverse Events: None
Company: None
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|